Opus Genetics Inc. Ordinary Shares IRD 深 滬
等待開盤 08-07 09:30:00 美东时间
1.10
-0.010
-0.90%
華盛通- 最 高1.13
- 今 開1.11
- 成交量 9.59万股
- 最 低 1.08
- 昨 收 1.11
- 總市值 6562.73万
- 52周最高 1.75
- 市盈率 靜 --
- 換手率 0.16%
- 52周最低 0.65
- 委 比 -63.57%
- 總股本 5966.12万
- 歷史最高 23.08
- 量 比 0.86
- 振 幅 4.50%
- 歷史最低 0.65
- 每 手 1
- 風險率 0.18%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
Opus Genetics, a clinical-stage biopharmaceutical company focused on developing gene therapies for inherited retinal diseases and small molecule therapies for ophthalmic disorders, announced that its CEO, George Magrath, will participate in a fireside chat at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025. The webcast will be available on Opus Genetics’ website under the Investors section. The company is advanc...
08-05 12:00
Demystifying Ocugen: Insights From 5 Analyst Reviews
Ratings for Ocugen (NASDAQ:OCGN) were provided by 5 analysts in the past three ...
08-04 21:03
AMGEN ANNOUNCES 2025 THIRD QUARTER DIVIDEND
THOUSAND OAKS, Calif., Aug. 1, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the third quarter of 2025. The div...
08-02 04:01
Shell Guides Q3 LNG Output At 6.7–7.3M Tonnes, Upstream At 1.7–1.9M boe/d; Sees Corporate Loss Of $500M–$700M And 2025 Capex At $20B–$22B
OUTLOOK FOR THE THIRD QUARTER 2025 Full year 2024 cash capital expenditure was $21 billion. Our cash capital expenditure range for the full year 2025 is expected to be within $20 - $22 billion. Integrated Gas
07-31 14:16
Analysts Are Bullish on Top Healthcare Stocks: Viking Therapeutics (VKTX), Opus Genetics (IRD)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
07-24 18:20
Opus Genetics Secures Funding for Gene Therapy Development
Opus Genetics ( ($IRD) ) has shared an announcement. On July 22, 2025, Opus Gen...
07-23 20:50
Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness
Opus Genetics collaborates with the Global RDH12 Alliance to advance its OPGx-RDH12 gene therapy for treating RDH12-related Leber congenital amaurosis (RDH12-LCA). The partnership aims to accelerate development, with $1.6 million funding from the Alliance and target IND filing by late 2025. The collaboration combines patient insights with Opus' expertise, aiming to restore vision for RDH12-LCA patients. Preclinical studies show promising results,...
07-23 12:00
CIVISTA BANCSHARES, INC. DECLARES THIRD QUARTER COMMON DIVIDEND
SANDUSKY, Ohio, July 22, 2025 /PRNewswire/ -- Civista Bancshares, Inc. (NASDAQ:CIVB) ("Civista") announced today that the Board of Directors has approved a quarterly dividend of 17 cents per...
07-23 04:50
Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review
Viatris' Phase 3 trial for pimecrolimus 0.3% in blepharitis did not meet its primary goal, prompting the company to reassess its development strategy.
07-19 02:17
Bajaj Finserv Gains IRDAI Approval for Allianz Stake Acquisition
Bajaj Finserv Limited ( ($IN:BAJAJFINSV) ) has provided an announcement. Bajaj ...
07-16 11:45
